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Genetic	defects	in	the	IFN-γ	response	pathway	cause	unique	susceptibility	to	intracellular	pathogens,	particu-
larly	mycobacteria,	but	are	rare	and	do	not	explain	mycobacterial	disease	in	the	majority	of	affected	patients.	
We	postulated	that	acquired	defects	in	macrophage	activation	by	IFN-γ	may	cause	a	similar	immunological	phe-
notype	and	thus	explain	the	occurrence	of	disseminated	intracellular	infections	in	some	patients	without	iden-
tifiable	immune	deficiency.	Macrophage	activation	in	response	to	IFN-γ	and	IFN-γ	production	were	studied	in	
whole	blood	and	PBMCs	of	3	patients	with	severe,	unexplained	nontuberculous	mycobacterial	infection.	In	all	
3	patients,	IFN-γ	was	undetectable	following	mitogen	stimulation	of	whole	blood,	but	significant	quantities	
were	detectable	in	the	supernatants	of	PBMCs	when	stimulated	in	the	absence	of	the	patients’	own	plasma.	The	
patients’	plasma	inhibited	the	ability	of	IFN-γ	to	increase	production	of	TNF-α	by	both	autologous	and	normal	
donor	PBMCs,	and	recovery	of	exogenous	IFN-γ	from	the	patients’	plasma	was	greatly	reduced.	Using	affinity	
chromatography,	surface-enhanced	laser	desorption/ionization	mass	spectrometry,	and	sequencing,	we	isolat-
ed	an	IFN-γ–neutralizing	factor	from	the	patients’	plasma	and	showed	it	to	be	an	autoantibody	against	IFN-γ.	
The	purified	anti–IFN-γ	antibody	was	shown	to	be	functional	first	in	blocking	the	upregulation	of	TNF-α	
production	in	response	to	endotoxin;	second	in	blocking	induction	of	IFN-γ–inducible	genes	(according	to	
results	of	high-density	cDNA	microarrays);	and	third	in	inhibiting	upregulation	of	HLA	class	II	expression	on	
PBMCs.	Acquired	defects	in	the	IFN-γ	pathway	may	explain	unusual	susceptibility	to	intracellular	pathogens	
in	other	patients	without	underlying,	genetically	determined	immunological	defects.
Introduction
Although one-third of the world’s population shows tuberculin 
skin reactivity indicative of previous exposure to Mycobacterium 
tuberculosis, less than 10% of those individuals develop clinical 
disease (1). The human immunological mechanisms that dis-
tinguish the majority of individuals, in whom these organisms 
are successfully contained, from the small minority who develop 
progressive mycobacterial diseases are largely unknown. Fur-
thermore, nontuberculous mycobacteria (NTMs) are ubiquitous 
organisms, yet clinical disease is virtually only seen in patients 
with underlying immunodeficiencies (2).
In 1996 our group, and that of Casanova, reported that muta-
tions in the gene encoding the IFN-γ receptor, leading to absence 
of expression of the IFN-γ receptor 1 chain, were the cause of famil-
ial susceptibility to mycobacterial infection (3, 4). Several different 
mutations in both genes encoding the IFN-γ receptor chains have 
subsequently been identified as the cause of disseminated atypical 
mycobacterial infections (5–9), disseminated BCG-osis (10–12), or 
tuberculosis (TB) (13). Individuals with defective IFN-γ receptor 
expression or function have a widespread defect in macrophage 
activation, which results in reduced production of TNF-α and 
other proinflammatory cytokines in response to IFN-γ and endo-
toxin (2, 3, 7, 9, 14), defective MHC class II expression in response 
to IFN-γ or antigenic stimulation, and reduced ability to present 
antigen to T cells (13, 15). A similar susceptibility to mycobacte-
rial infection due to mutations in the genes for the IL-12 p40 sub-
unit and the IL-12 Rβ1 subunit (16–18) and in the STAT1 gene 
(19) has also been reported. These observations have established 
that upregulation of macrophage mycobactericidal mechanisms 
through the IFN-γ or IL-12 pathway is critical for a successful 
immune response to mycobacteria (20, 21). However, genetic 
defects in the IFN-γ pathway are rare and are unlikely to explain 
the majority of cases in both adults and children with unusual sus-
ceptibility to mycobacteria. In this report, we describe 3 patients 
with severe, progressive NTM infection, in whom autoantibodies 
against IFN-γ have resulted in a phenotype similar to that seen 
with mutations in the IFN-γ response pathway.
Results
Case descriptions
Patient 1. A 46-year-old, previously healthy UK resident presented 
in August 1993 with a 2-week history of weight loss, joint pains, 
abdominal pain, and fever. She was initially thought to be suffer-
ing from Crohn disease and was treated with corticosteroids and 
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an elemental diet. Her symptoms worsened despite this treatment, 
and she subsequently underwent a right hemicolectomy, after 
which her condition improved. However, over the next year, she 
again developed abdominal and bone pains, fevers, and weight loss, 
followed by stridor and multiple soft tissue masses over her left 
clavicle and neck. Tracheal obstruction due to a granulomatous 
mass was demonstrated, as well as evidence of multiple inflam-
matory bone lesions. A biopsy of the neck masses and clavicular 
mass showed multiple granulomata containing acid-fast bacilli. 
Mycobacterium avium intracellulare (MAI) was subsequently cultured 
from the biopsies of the neck mass and bones. She was treated 
with rifabutin, clarithromycin, ethambutol, and clofazimine but 
continued to deteriorate, exhibiting wasting and fevers. Treatment 
with IFN-γ (Immukin; Boehringer Ingelheim) was commenced at 
a slowly escalating dose. She experienced severe malaise, myalgia, 
and fevers with the initial doses but subsequently tolerated it well. 
She progressively improved on this treatment, gained weight, 
and became symptom free. All anti-microbials were discontinued 
after 42 months. She currently remains healthy on treatment with 
100 µg/m2 IFN-γ 3 times weekly.
Patient 2. A 32-year-old South African male presented to hospital 
in November 2000 with back pain and episodic fevers. He had been 
treated with nonsteroidal antiinflammatory agents, antibiotics, 
and a 3-month course of corticosteroids without improvement. 
On admission, he was found to have a paraspinal mass and wedge 
compression of the T7 vertebra. Fine needle biopsy revealed acid-
fast bacilli, and cultures yielded MAI. He was treated with clar-
ithromycin, rifabutin, and ethambutol and slowly improved.
Patient 3. A 59-year-old UK resident presented in April 2002 
with a 6-week history of fever, breathlessness, and weight loss. 
Radiography showed extensive destruction of her left lung, with 
consolidation, cavitation, and bronchiectatic changes in both 
lung fields. Mycobacterium fortuitum was cultured from her bron-
choalveolar fluid, as well as Aspergillus species. Despite treatment 
with nontuberculous mycobacterial drugs and amphotericin, 
her condition deteriorated until she required ventilatory assis-
tance for respiratory failure. With ongoing treatment over time, 
she slowly improved.
IFN-γ production in response to mitogen in whole blood  
and isolated PBMCs
Stimulation of whole blood from healthy controls using the mito-
gen phytohemagglutinin (PHA; or phorbol 12-myristate 13-ace-
tate/ionomycin [PMA/ionomycin] in the case of patient 2) resulted 
in the production of large quantities of IFN-γ. In contrast, when 
the patient’s whole blood was stimulated, IFN-γ was not detectable 
in the supernatant plasma. However, in the absence of their own 
plasma, the patients’ washed PBMCs produced large quantities of 
IFN-γ in response to mitogens, although less than that of the con-
trols (Figure 1). These findings suggested the presence of a plasma 
factor inhibiting the detection of IFN-γ.
Impaired upregulation of macrophage TNF-α production  
in response to exogenous IFN-γ
The ability of purified IFN-γ to activate macrophages to produce 
TNF-α in response to endotoxin was assessed. In the presence of 
control serum, production of endotoxin-induced TNF-α increased 
when PBMCs from either patients or healthy controls were exposed 
to IFN-γ. In contrast, in the presence of the patients’ serum, TNF-α 
production by either the patients’ or control PBMCs was markedly 
diminished upon exposure to a range of concentrations of exog-
enous IFN-γ (Figure 2).
Recovery of exogenous IFN-γ from patients’ or control sera
In order to establish whether the patients’ sera contained a fac-
tor that neutralized or degraded IFN-γ, we added increasing con-
centrations of recombinant IFN-γ to patients’ or control serum 
and then measured the concentration of IFN-γ recovered. The 
quantity of exogenous IFN-γ detected in patients’ serum was 
markedly reduced. Only upon addition of 106 pg/ml was IFN-γ 
measurable (Figure 3).
Purification and identification of the IFN-γ–neutralizing factor 
from patients’ sera
To purify the IFN-γ–neutralizing factor, we passed patient or 
control serum through an IFN-γ affinity column and then 
sequentially eluted the serum factors binding to the IFN-γ with 
increasing concentrations of sodium chloride followed by 0.1 M 
glycine HCl. The IFN-γ–neutralizing activity was recovered only 
in the fractions eluting at low pH. No activity was found in any 
other fraction or in fractions from control serum subjected to 
identical fractionation procedures.
To establish the identity of the IFN-γ–neutralizing factor, we 
subjected the active IFN-γ–neutralizing fractions recovered from 
the affinity column to analysis by SDS-PAGE electrophoresis, 
surface-enhanced laser desorption/ionization (SELDI) mass 
spectrometry, and N-terminal sequencing. SDS-PAGE analysis of 
the active fractions from patient 1 revealed a single band with 
a molecular weight of 150 kDa on unreduced gels, whereas the 
other patients had high-molecular-weight bands above 400 kDa. 
After treatment with dithiothreitol, the high-molecular-weight 
bands were reduced to 2 smaller bands of approximately 50 kDa 
and 30 kDa, respectively (data not shown). The bands were then 
either electroblotted to membranes for Edman degradation or 
excised for peptide mapping. The tryptic peptides were resolved 
using SELDI mass spectrometry. ProFound software (http://
Figure 1
IFN-γ production in response to mitogen stimulation in whole blood 
(WB) and isolated PBMCs. IFN-γ was not detected in patients’ plasma 
derived from whole blood after stimulation with PHA (or PMA/iono-
mycin in patient 2), whereas large quantities of IFN-γ were detected 
when isolated PBMCs were studied in the absence of patient plasma. 
IFN-γ production in PBMCs is expressed as a percentage of that in 
blood of healthy controls studied in the same experiments. Superna-
tants from triplicate samples of whole blood or PBMCs were pooled 
for each patient and control and assayed in duplicate by ELISA. The 
coefficients of variation (CVs) in each assay were less than 5%.
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prowl.rockefeller.edu/profound_bin/WebProFound.exe) was used 
to search the NCBI database in order to establish the identities of 
the proteins and their peptic digests. Finally, confirmation of the 
identity of the proteins was established by N-terminal sequenc-
ing undertaken in the Department of Biochemistry, University 
of Newcastle (United Kingdom). The IFN-γ–neutralizing factor 
in patient 1 was thus identified as an IgG3 antibody, and those of 
patients 2 and 3 were found to be IgM antibodies.
Specificity of anti–IFN-γ antibody and determination of serum 
anti–IFN-γ IgG and anti-IgM titers by ELISA
In order to establish whether the identified antibodies were specific 
to our NTM patients or could also be found in patients with other 
mycobacterial diseases, such as TB, we repeated complementary 
experiments using serum from 13 patients with TB, 8 tuberculin-
positive healthy contacts of TB patients (patients with latent TB 
infection [LTBI]), and 11 tuberculin-negative healthy individuals.
In contrast to our findings in the 3 NTM patients, TNF-α pro-
duction in response to LPS and IFN-γ was not impaired in PBMCs 
from healthy controls when serum from the 3 groups described 
above was added. There were no significant differences in the 
median ratios calculated from the levels of TNF-α produced in 
response to LPS plus IFN-γ versus LPS alone when plasma from 
TB patients (median, 615 pg/ml; range, 194–1,011 pg/ml), patients 
with LTBI (median, 780 pg/ml; range, 708–1,041 pg/ml), and 
the tuberculin-negative individuals (median, 553 pg/ml; range, 
324–776 pg/ml) was used. The amount of exogenous IFN-γ recov-
ered from the serum of the TB patients and patients with LTBI did 
not differ from that recovered from the serum of tuberculin-nega-
tive individuals (data not shown).
Furthermore, we sought evidence that active TB or infection 
could have produced similar antibodies to those seen in our 
patients with NTM by using an anti–IFN-γ IgG– or IgM–specific 
ELISA. No significant ODs were detectable in the TB-infected/
diseased individuals (mean, 0.01) compared with the tuberculin-
negative individuals (mean, 0.009), and high ODs were detected in 
the NTM patients’ serum (mean, 0.334).
Functional activity of the purified IFN-γ–binding antibody 
according to high-density cDNA microarrays
In order to confirm that the anti–IFN-γ antibodies were func-
tional, we studied the upregulation of IFN-γ–inducible genes by 
microarray analysis, in the presence or absence of the purified 
antibody. As shown in Figure 4, exposure of PBMCs to IFN-γ 
induced changes in multiple genes. In the presence of the puri-
fied anti–IFN-γ antibody, a shift in the gene expression profile was 
seen, which was not observed in the presence of the nonspecific 
control antibody. The majority of genes of known function that 
were identified to be induced (more than 2.5-fold) by IFN-γ treat-
ment at each time point (determined by subtracting the mean 
log2 ratio of the abundance of mRNA of untreated from that of 
IFN-γ–treated PBMCs)	were expressed at an at least 2.5-fold lower 
level after treatment with IFN-γ and the purified anti–IFN-γ anti-
body (determined by subtracting the mean log2 ratio of the abun-
dance of mRNA of the nonspecific antibody–treated from that 
of the anti–IFN-γ antibody–treated PBMCs). Of the 48 genes of 
known function upregulated after 2 hours treatment with IFN-γ, 
43 (89.6%) showed greater then 2.5-fold reduction in expression in 
the presence of purified anti–IFN-γ antibody. Similarly, at 6 hours, 
41 of 46 genes (89.1%) of known function induced by IFN-γ were 
repressed. At 21 hours, 111 of 119 (93.2%) known genes induced by 
IFN-γ were repressed by 2.5-fold or more in response to treatment 
with the purified anti–IFN-γ antibody.
Expression of the gene encoding TNF-α was downregulated over 
time in the presence of the antibody (Figure 4, cluster I), which 
confirmed the impaired upregulation seen in PBMCs as shown in 
Figure 1. Significance analysis of microarrays (SAM) was used to 
identify genes significantly differentially expressed throughout 
the time course between the response of PBMCs to treatment with 
IFN-γ treatment alone and that to treatment with IFN-γ togeth-
er with the purified anti–IFN-γ antibody. This unpaired 2-class 
comparison identified 120 cDNA elements, corresponding to 64 
Figure 2
IFN-γ–induced TNF-α upregulation is inhibited in the presence 
of patients’ sera. PBMCs from healthy donors showed marked 
upregulation of TNF-α production when exposed to concentrations of 
IFN-γ as low as 20 ng/ml in the presence of control serum (black) or 
fetal calf serum (blue). Addition of IFN-γ failed to upregulate TNF-α 
production in the presence of patients’ serum (red) at concentrations 
of IFN-γ from 20 to 100 ng/ml, and upregulation was only seen at very 
high concentrations. The figure shows a representative experiment 
using serum from patient 1. All samples were set up in triplicate and 
supernatants pooled for IFN-γ ELISA measurements in duplicate wells. 
The CV between duplicates was less than 5%.
Figure 3
Recovery of IFN-γ from patient or control serum. Increasing concen-
trations of purified IFN-γ were added to patient (red) or control serum 
(blue). After 1 hour incubation at room temperature, the concentration 
of IFN-γ in the serum was determined by ELISA. Exogenous IFN-γ 
was not recovered from the patients’ serum even when added at con-
centrations 5 logs greater than that required for recovery from normal 
serum. The figure shows a representative experiment using serum 
from patient 1. All samples were set up in triplicate and supernatants 
pooled for IFN-γ ELISA measurements in duplicate wells. The CVs 
between duplicates were less than 5%.
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Figure 4
High-density cDNA microarrays showing functional activity of IFN-γ–binding antibody. PBMCs from a healthy donor were exposed to 4 different 
conditions — no treatment with IFN-γ or antibody (control); IFN-γ alone; IFN-γ with the patient antibody (pt Ab); and IFN-γ with a nonspecific anti-
body (ns Ab) — each over 4 time points (0, 2, 6, and 21 hours). After data selection and normalization, we filtered for genes demonstrating at least 
2.5-fold change from baseline at any 2 of the time points surveyed. The resulting genes were ordered by agglomerative hierarchical clustering (aver-
age linkage method) using Cluster software. The genes are displayed in rows, time points in columns. Induced genes are depicted in red, repressed 
genes in green. Gray represents missing data. When the patient’s purified anti–IFN-γ antibody was present with IFN-γ, the gene expression profile 
most closely resembled that of the control subject. Cluster I shows TNF genes; cluster II, genes most affected by the presence of the antibody; and 
cluster III, expression of IFN-γ.
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unique genes of known function (detailed in Table 1) that were sig-
nificantly underexpressed on addition of the purified anti–IFN-γ 
antibody. Many of these genes have been previously shown to be 
induced by IFN-γ stimulation (22, 23).
In addition, the hypergeometric distribution was used to deter-
mine whether the number of genes previously demonstrated to 
be induced by IFN-γ was significantly enriched in the subset of 
genes upregulated in response to IFN-γ and downregulated after 
treatment with the purified anti–IFN-γ antibody. The number of 
IFN-γ–induced genes in this subset was found to be highly sig-
nificant (P = 4.5 × 10–23). This microarray analysis demonstrated 
that the purified anti–IFN-γ antibody recovered from patient 1 
was functional and able to repress a subset of genes induced in 
PBMCs in response to IFN-γ treatment.
Functional activity of the purified IFN-γ–binding antibody  
as determined by induction of HLA class II expression
In order to confirm that the inhibition of IFN-γ–responsive 
genes by the patients’ antibodies also corresponded to changes 
in induced protein expression, we studied the changes in HLA 
class II expression induced in PBMCs in the presence or absence 
of the anti–IFN-γ antibody. As shown in Figure 5, upregulation 
of HLA class II expression was inhibited by the anti–IFN-γ anti-
body, which was not observed with the nonspecific antibody on 
the leukocyte population. The baseline mean fluorescence index 
of unstimulated cells was 585 ± 9 for HLA-DR and 3 ± 0.1 for 
the isotope control, IgG2a antibody. The addition of IFN-γ at 1 
ng/ml resulted in an increase in the mean fluorescence intensity 
to 2,372 ± 62 for HLA-DR expression as compared with base-
line. The mean fluorescence intensity for HLA-DR in the cells 
with antibody alone with 1:10 dilution was 857, which indicated 
some nonspecific upregulation of HLA-DR expression. However, 
addition of the same dilution of antibody to the IFN-γ–stimu-
lated cells resulted in a mean fluorescence intensity of only 1,236, 
which indicated significant inhibition of the induction due 
to IFN-γ (P = 0.0002).
Discussion
Severe, progressive, and disseminated mycobacterial infections 
are well recognized in association with AIDS, during immunosup-
pressive treatment and in patients with inherited immunological 
defects such as severe combined immunodeficiency. More recently, 
the identification of patients with genetic defects in the IFN-γ/ 
IL-12 pathway who show a unique susceptibility to mycobacteria 
has provided conclusive evidence that IFN-γ plays a key role in con-
taining intracellular infections and has explained the occurrence 
of unusual mycobacterial infections in patients who do not have 
recognizable defects in their cellular immunity (20, 21).
In this report, we have described a novel mechanism underlying 
a newly identified clinical syndrome of progressive mycobacterial 
infection in patients who have no previously recognizable immu-
nological disorder. The clinical features of our patients are simi-
lar to those with genetic defects in the IFN-γ/IL-12 pathway in 
that they present with progressive or disseminated infection with 
mycobacteria of low virulence. The insidious, slowly progressive 
nature of the infection and the nonspecific presenting features 
including weight loss, fevers, and bone pain resulted in consider-
able diagnostic difficulty in each case. As in the case of patients 
with genetic defects in the Th1-type cytokine pathways, response 
to antimicrobial treatment was slow and incomplete, even when 
the mycobacterial infection was recognized and appropriate 
treatment instituted.
All 3 patients have been shown to have high titers of autoan-
tibodies that specifically bind to IFN-γ and inhibit its ability to 
activate macrophage function.
Studied in serum-free medium, PBMCs from all patients showed 
detectable IFN-γ production in response to PHA or PMA/ionomy-
cin. There may be several explanations for the fact that IFN-γ pro-
duction by the patients’ PBMCs in the absence of their serum was 
reduced compared with that by control PBMCs. First, complete 
removal of patient plasma may not have been achieved during 
recovery of the cells, and in view of the high titers at which the 
antibody can impair IFN-γ recovery, even traces of plasma may 
have blocked full IFN-γ recovery. Second, our previous studies of 
patients with IFN-γ receptor deficiency have shown reduced IFN 
production in response to PHA in a patient unable to respond to 
IFN-γ due to absence of the IFN-γ receptor (15).
The likely explanation for this observation is that IFN-γ regu-
lates the level of its own production, in some form of feedback 
loop. Patients with anti–IFN-γ antibodies may have a similar defect 
in this feedback loop and thus resemble patients with IFN-γ recep-
tor deficiency in this immunological phenotype. In contrast, in 
the presence of their own plasma, IFN-γ is undetectable, and func-
tional IFN-γ responses are markedly impaired. We have confirmed 
the functional activity of the anti–IFN-γ antibody in inhibiting 
IFN-γ responses using 3 different methods: (a) treatment with 
Figure 5
Inhibition of HLA class II expression by IFN-γ–binding antibody. The 
antibody isolated from the serum of the patient is able to neutralize 
the function of IFN-γ: a 1:10 dilution of the antibody in the cell culture 
decreases the effect of IFN-γ in upregulating HLA-DR expression on 
monocytes. (A) Results expressed as mean fluorescence index (MFI) 
of HLA-DR on the surface of the monocyte population, based on tripli-
cate measurements. (B) Representative plot defining HLA-DR positiv-
ity. A monocyte gate was applied to the PBMCs stained for HLA-DR.
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Table 1
List of genes significantly differentially expressed between PBMCs exposed to IFN-γ alone and those treated with IFN-γ and the patient 
anti–IFN-γ antibody
Gene ID Full name Mean fold change
UBD Ubiquitin D –171.23
MIG Chemokine (C-X-C motif) ligand 9 –17.94
FCGR1A Fc fragment of IgG, high-affinity Ia, receptor for (CD64) –15.45
SERPING1 Serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor) –14.49
SCYB10 Chemokine (C-X-C motif) ligand 10 –14.25
WARS Tryptophanyl-tRNA synthetase –13.98
SRM300 Serine/arginine repetitive matrix 2 –12.99
GBP1 Guanylate binding protein 1, interferon-inducible, 67 kD –10.49
PIK3C3 Phosphoinositide-3-kinase, class 3 –7.55
LOC51056 pepA, cytosol aminopeptidase –5.74
TNFRSF5 CD40, CD40 antigen (TNF receptor superfamily member 5) –5.45
EPB41 Erythrocyte membrane protein band 4.1 –4.74
RAB11A RAB11A, member RAS oncogene family –4.72
TNFSF10 TNF (ligand) superfamily, member 10 –4.56
CD4 CD4 antigen (p55) –4.42
TAP1 Transporter 1, ATP-binding cassette, subfamily B (MDR/TAP) –4.37
ICSBP1 IRF8, Interferon regulatory factor 8 –4.31
BRCA1 Breast cancer 1, early onset –4.14
GLS Glutaminase –3.98
SCYA8 CCL8, chemokine (C-C motif) ligand 8 –3.97
STAT1 Signal transducer and activator of transcription 1 –3.83
ATF3 Activating transcription factor 3 –3.78
GBP2 Guanylate binding protein 2, interferon-inducible –3.77
RPC RNA 3′-terminal phosphate cyclase –3.76
TBX21 T-box 21 –3.72
MRPL23 Mitochondrial ribosomal protein L23 –3.60
SSI-1 SOCS1, suppressor of cytokine signaling 1 –3.59
INHBA Inhibin, beta A (activin A, activin AB alpha polypeptide) –3.54
IRF4 Interferon regulatory factor 4 –3.49
SEPX1 Selenoprotein X, 1 –3.44
IRF1 Interferon regulatory factor 1 –3.42
VAMP5 Vesicle-associated membrane protein 5 (myobrevin) –3.39
UBE2L6 Ubiquitin-conjugating enzyme E2L 6 –3.39
GLB1 Galactosidase, beta 1 –3.38
TXN Thioredoxin –3.28
RPS9 Ribosomal protein S9 –3.26
HM74 GPR109B, G protein–coupled receptor 109B –3.23
CHK CHKA, Choline kinase alpha –3.17
CASP10 Caspase 10, apoptosis-related cysteine protease –3.14
KLF4 Kruppel-like factor 4 (gut) –3.13
PSMB8 Proteasome (prosome, macropain) subunit, beta type, 8 –3.12
RALB v-ral simian leukemia viral oncogene homolog B –3.11
MNAT1 Menage a trois 1 (CAK assembly factor) –3.07
UBE3A Ubiquitin protein ligase E3A –3.07
LIMK2 LIM domain kinase 2 –3.07
H4FG H4 histone family, member G –3.03
TARBP1 TAR (HIV) RNA-binding protein 1 –3.02
MHC2TA MHC class II transactivator –2.99
CCNA1 Cyclin A1 –2.89
CD69 CD69 antigen (p60, early T cell activation antigen) –2.88
RPS6KA5 Ribosomal protein S6 kinase, 90 kD, polypeptide 5 –2.87
IL2RA Interleukin 2 receptor, alpha –2.82
UBE1L Ubiquitin-activating enzyme E1-like –2.80
ICAM1 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor –2.80
AIM2 Absent in melanoma 2 –2.75
RGS1 Regulator of G-protein signaling 1 –2.73
DNAM-1 CD226, CD226 antigen –2.67
XAP4 HBV-associated factor –2.67 
CSF2RB Colony stimulating factor 2 receptor, beta –2.64
CISH Cytokine inducible SH2-containing protein –2.60
APOL3 Apolipoprotein L, 3 –2.58
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) –2.56
PSTPIP2 Proline-serine-threonine phosphatase interacting protein 2 –2.53
IFI35 Interferon-induced protein 35 –2.51
SAM was used to determine genes significantly differentially expressed between PBMCs exposed to IFN-γ alone and those treated with IFN-γ and the 
patient anti–IFN-γ antibody. A total of 120 genes was identified at a false discovery rate of less than 1 (of the median) with a delta value of 0.9243. Only 
genes downregulated by at least 2.5-fold in samples treated with IFN-γ and patient antibody were considered to be underexpressed. The magnitude of 
underexpression is marked as mean fold change. Multiple array elements of the same gene, unknown genes, and genes coding for hypothetical proteins 
(22) have been removed from this table. The remaining 64 unique genes are ranked by fold change.
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endotoxin, which impaired TNF-α production in the presence of 
the patients’ serum; (b) cDNA microarray analysis, which showed 
that a large number of IFN-γ–responsive genes were blocked in the 
presence of purified antibody; and (c) induction of HLA class II 
upregulation, which inhibited upregulation of IFN-γ.
These results establish definitively that these IFN-γ antibodies 
are functional in blocking the extensive cellular changes induced 
by IFN-γ. Furthermore, the gene expression studies add to the 
existing knowledge about genes that are IFN-γ responsive (23) 
and provide an indication of the global immune dysfunction that 
might occur in the presence of IFN-γ–blocking agents. It is not sur-
prising, therefore, that the antibodies appear to produce an immu-
nological phenotype similar to that caused by genetically deter-
mined mutations in the IFN-γ receptor genes (11, 14, 15, 20, 21, 
24). The observation that inhibition of IFN-γ by autoantibodies 
produces marked susceptibility to mycobacteria further confirms 
the importance of IFN-γ in determining resistance to mycobacte-
rial infection in humans.
The microarray data also showed an effect on the TNF-α signa-
ture; expression of the gene encoding TNF-α was downregulated 
over time in the presence of the anti–IFN-γ antibody. The role of 
TNF-α and its inhibition in mycobacterial infection is of obvious 
importance, and our data confirm the close interaction between 
IFN-γ and TNF-α, which are known to be implicated in the con-
tainment of mycobacteria and granuloma formation (25). It is pos-
sible that the changes in TNF-α signal represent a possible mecha-
nism of refractory infection, but we interpret these changes as a 
consequence of the impaired IFN-γ signal rather than its cause.
Since the first presentation of patient 1 described herein, 
there have been reports of 2 additional patients with aggressive 
mycobacterial infection in whom anti–IFN-γ antibodies have 
been documented (26, 27). Results of our comprehensive study 
of the functional effects of the anti–IFN-γ antibody in blocking 
IFN-γ–induced genes together with those of the 2 additional 
reports suggest a novel mechanism of immune dysfunction and 
susceptibility to mycobacteria.
The major questions arising from these cases are why an auto-
antibody against this critical cytokine has developed and whether 
this mechanism accounts for susceptibility in other patients with 
disseminated intracellular infections. The fact that in a relatively 
short period 5 patients of different origin and ethnicity have been 
reported suggests that this disorder may be relatively common.
Anti-cytokine autoantibodies have been reported in a number of 
other human infectious or inflammatory conditions (28), includ-
ing viral infections (29), HIV (30), and EBV (31). The autoantibod-
ies may arise through cross-reactivity between infectious agents 
and host proteins; through exposure to bacterial production of 
novel epitopes during the interaction of human antigens and 
those of the pathogen; or due to a failure in self tolerance. A num-
ber of viruses including EBV are known to encode proteins with 
homology to human cytokines. EBV encodes a viral homolog of 
IL-10 that is believed to be responsible for eliciting autoantibodies 
against IL-10 (31). We have preliminary evidence that the purified 
anti–IFN-γ antibodies from our patients do recognize mycobacte-
rial antigens, but further studies are required to establish whether 
the antibodies do indeed cross-react with mycobacterial proteins.
Anti–IFN-γ antibodies have been reported previously in humans. 
Turano et al. (32) reported the presence of anti–IFN-γ antibodies 
in normal individuals that interfered with Fc receptor and HLA-
DR expression but did not block antiviral activity. Madariaga et 
al. (33) reported the presence of antibodies to IFN-γ in patients 
with M. tuberculosis infection, but their functional significance was 
not established. In their study, the presence of antibody did not 
prevent the detection of IFN-γ in the plasma. This is in contrast 
to the finding in our patients, where the presence of antibody 
blocked both the recovery and function of IFN-γ. Further studies 
are required to establish whether other patients with disseminated 
mycobacterial disease, not explained by known immunodeficien-
cies, have IFN-γ autoantibodies similar to those observed in our 
patients. In our own experiments, we have not detected impaired 
recovery of IFN-γ from plasma of patients with typical TB.
Our results support the hypothesis that susceptibility to 
intracellular pathogens in humans might originate from a range 
of different acquired or inborn defects in macrophage activation 
by IFN-γ. Autoantibody-mediated defects in this pathway repre-
sent a novel immunological defect in the handling of mycobacteria 
and should be considered in the investigations of patients with 
persistent or unusual mycobacterial infection.
Methods
Routine immunological investigations. All 3 patients were extensively inves-
tigated to exclude common cellular or humoral immunological defects. 
Results of tests for HIV antibodies were negative and the numbers of 
T cells and subclasses normal. Results of the reduction of nitroblue tetrazo-
lium reduction test were normal; C3, C4, and total hemolytic complement 
levels were normal; results of tests for antibodies against nuclear antigens 
and DNA, rheumatoid factor, antineutrophil cytoplasmic antibodies, and 
antiphospholipid antibodies were negative. Immune responses to vaccine 
antigens were normal. IFN-γ receptor deficiency and IL-12 and its receptor 
deficiency were excluded, as described previously (3, 4, 34).
Experimental investigations. All blood samples from patients and controls 
were taken with informed consent and approval of the Clinical Ethics 
Committees of St. Mary’s Hospital (London, United Kingdom), the North-
wick Park Hospital, and the Groote Schuur Hospital. Whole blood was 
collected into sterile bottles containing either 10 U/ml of preservative-free 
heparin or no anticoagulants. Plasma was obtained by centrifugation of 
heparinized venous blood; serum was obtained by centrifugation of clot-
ted blood samples. PBMCs were obtained over a Ficoll-Hypaque gradient, 
using standard protocols.
The 3 individuals with severe NTM infection reported in this article are 
referred to as patients. Healthy adult individuals, whose blood/PBMCs 
were used as controls in the functional assays described below, are referred 
to as controls.
Plasma from 3 additional groups of subjects — (a) 13 subjects with active 
TB; (b) 8 subjects with LTBI; and (c) 11 tuberculin-negative healthy sub-
jects — was used to establish the specificity of the findings for patients with 
NTM infection, as described below.
Production of IFN-γ in whole blood and PBMCs. The production of IFN-γ in 
response to the mitogen PHA (Sigma-Aldrich) or PMA and ionomycin was 
assessed in heparinized whole blood diluted 1:10 with RPMI tissue culture 
medium (Invitrogen Corp.) as described previously (35). PHA (10 µg/ml) was 
added to aliquots of blood and incubated for 3 hours at 37°C. The concen-
tration of IFN-γ was measured in the supernatant by ELISA using antibody 
pairs from BD Biosciences — Pharmingen. For assessment of IFN-γ produc-
tion in the absence of plasma, PBMCs prepared from patients’ or control 
blood were plated out at a concentration of 1 × 106/ml in RPMI culture 
medium and stimulated with 10 µg/ml PHA for 3 days. The supernatant was 
recovered, and the concentration of IFN-γ determined as described above.
Effect of patients’ plasma on IFN-γ–induced macrophage activation. The abil-
ity of IFN-γ to upregulate macrophage TNF-α production in response to 
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 115   Number 9   September 2005 2487
endotoxin was assessed as described previously (2, 15). PBMCs from patients 
or healthy controls were recovered from freshly drawn heparinized blood 
by Ficoll-Hypaque gradient separation and plated out at a concentration of 
1 × 106/ml in the presence of 10% patient or control plasma. The concentra-
tion of TNF-α in the supernatant was determined by ELISA after stimulation 
for 3 hours with E. coli endotoxin (0.2 ng/ml; Sigma-Aldrich) in the presence 
of concentrations of IFN-γ ranging from 0 to 10,000 ng/ml for 3 hours.
Detection of IFN-γ–neutralizing factor. Exogenous IFN-γ was added to 
patients’ or control plasma, or separated fractions of plasma, in concen-
trations ranging from 0 to 10,000 ng/ml. After samples were mixed and 
incubated for 1 hour, the concentration of recovered IFN-γ in the plasma 
was determined by ELISA.
Determination of serum anti–IFN-γ IgG and IgM titers by ELISA. ELISA plates 
were coated with anti-human IFN-γ antibody (554548; BD Biosciences 
— Pharmingen) at 2 µg/ml in carbonate buffer (pH 8.2) overnight at 4°C. 
After washing with PBS containing 0.1% Tween-20, wells were blocked with 
PBS containing 10% FCS. Following washing, the IFN-γ–binding sites were 
saturated with 5 µg/ml IFN-γ during overnight incubation at 4°C. Control 
wells were not treated with IFN-γ. Plates were washed again, and serially 
diluted serum samples (dilutions: 1:32, 1:64, 1:128, 1:256, 1:1,024) were 
added in duplicate to the IFN-γ–treated and untreated wells. Following 
overnight incubation at 4°C, plates were washed, and peroxidase-conju-
gated anti-IgG antibody (A6029; Sigma-Aldrich) or anti-IgM antibody 
(A6907; Sigma-Aldrich) was added at dilutions of 1:2,000 (anti-IgG) or 
1:3,000 (anti-IgM) for 1 hour at room temperature. After extensive wash-
ing, wells were developed using tetramethylbenzidine substrate (P4922; 
Sigma-Aldrich), and ODs were read at 450 nm. For determination of the 
anti–IFN-γ IgG or IgM titers, the mean OD values in the IFN-γ–untreated 
control wells were subtracted from the mean OD values in the IFN-γ–treat-
ed wells for each sample at each dilution.
Purification of the IFN-γ–binding factor. An IFN-γ affinity column was 
prepared by incubating 0.5 mg of IFN-γ with activated Sepharose beads 
(Amersham Pharmacia Biotech) according to the manufacturer’s instruc-
tions. After unbound IFN-γ was removed and the column was equilibrated 
to pH 7 in PBS, 1 ml of either patient or control serum diluted 1:2 in PBS 
was passed over the column. After unbound plasma was washed off with 2 
column volumes of PBS, the bound factors were sequentially eluted with 
0.5 M, 1 M, and 2 M NaCl, followed by 0.1 M glycine HCl (pH 3). The elu-
ate recovered with each step was dialyzed against PBS, concentrated to the 
original volume, and tested for the ability to neutralize IFN-γ as described 
above. The identity of the IFN-γ–binding factor was established by SDS-
PAGE, N-terminal amino acid sequencing (performed at the Department 
of Biochemistry, University of Newcastle), and peptide mapping performed 
by SELDI mass spectrometry (36).
Confirmation of function of the anti–IFN-γ antibody through the use of high-
density cDNA microarrays. In order to confirm that the IFN-γ autoanti-
bodies found in our patients were functional in blocking IFN-γ–induced 
effects, we studied the genes in PBMCs, whose expression was altered 
by IFN-γ in the presence of affinity-purified anti–IFN-γ antibodies 
from patient 1. PBMCs from a healthy donor were plated at a density of 
4 × 106/ml in RPMI culture medium and exposed to IFN-γ at a concen-
tration of 1 ng/ml, or an equivalent volume of PBS, in the presence or 
absence of either purified anti–IFN-γ antibody or a nonspecific antibody 
(isotype control IgG2a).
At sequential time points from 0–21 hours, RNA was extracted using a 
standard phenol chloroform isopropanol extraction technique. The RNA 
was reverse-transcribed to cDNA and amplified using a modified Eberwine 
technique (MessageAmp aRNA kit; Ambion Inc.) as described previous-
ly (37–39). The RNA-derived cDNA sample was labeled with Cy5-dUTP 
and combined in equal quantity with a similarly labeled reference cDNA 
(Cy3-dUTP), which had been derived from a pool of RNA from a panel of 11 
human cell lines (Universal Human Reference RNA; Stratagene). The probe 
was washed, concentrated, and competitively hybridized to custom-printed 
cDNA microarrays containing 37,632 elements for approximately 18,000 
unique human genes. The slides were scanned using a GenePix 4000A 
microarray scanner (Axon Instruments). Areas of the array with blemishes 
or of poor quality were flagged and excluded from analysis (GenePix Pro 
5.0; Axon Instruments). Using the Stanford MicroArray Database (http://
genome-www5.stanford.edu//), we filtered data to include only cDNA ele-
ments with fluorescence intensities of at least 2.5-fold over background in 
both Cy3 and Cy5 channels and that were present on at least 80% of the 
arrays. The remaining gene expression ratios were normalized and the data 
zero transformed using a custom-designed Microsoft Excel macro (C. Liu, 
http://genetics.stanford.edu/∼cliu/DataProc_Template_v1_2 8.xls). The 
transformed data were hierarchically clustered using Cluster version 2.11 
and the results displayed using Treeview software version 1.60 (http://rana.
lbl.gov/EisenSoftware.htm) (40).
The hypergeometric distribution was used to determine whether genes 
known to be induced by IFN-γ were significantly enriched in the subset of 
genes induced by IFN-γ and whether those genes were then downregulated 
in response to treatment with the purified anti–IFN-γ antibody. The hyper-
geometric p value was calculated (41) using the following formula:
Equation 1
where N is the total number of named genes in the filtered population; 
A is the number of genes known to be induced by IFN-γ in the filtered 
population (22, 23), x is the number of named genes previously identified 
as induced by IFN-γ that were upregulated in response to IFN-γ treatment 
and repressed by treatment with the purified anti–IFN-γ antibody; and 
n is the total number of known genes induced in response to IFN-γ and 
repressed by treatment with the purified anti–IFN-γ antibody.
In addition, the statistical package SAM (version 1.15; http://www-stat.
stanford.edu/~tibs/SAM/) was used to identify genes significantly differ-
ently expressed in the normalized data sets (42).
Confirmation of function of the anti–IFN-γ antibody by induction of HLA class II 
expression. IFN-γ upregulates the expression of HLA-DR on leucocytes. We 
utilized this upregulation to assess the ability of the anti–IFN-γ antibody 
to neutralize this functional effect of IFN-γ. PBMCs from a healthy human 
donor were plated in a 96-well tissue culture plate in triplicate at a den-
sity of 105 cells per well. Serial dilutions of the affinity-purified anti–IFN-γ 
antibody were added to the cells. IFN-γ was added to the wells at a concen-
tration of 1 ng/ml. Control wells containing cells with IFN-γ and a non-
specific antibody; cells without IFN-γ but with either anti–IFN-γ antibody 
or nonspecific antibody alone; or unstimulated cells without antibody 
were also included. The plate was incubated overnight in a CO2 incubator. 
The cells were then stained for HLA-DR expression using commercially 
available conjugate antibodies and analyzed by FACS (FACSCalibur Flow 
Cytometer; BD Biosciences) with CELLQuest software (BD Biosciences).
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